US HB3777 | 2009-2010 | 111th Congress

Status

Spectrum: Partisan Bill (Democrat 3-0)
Status: Introduced on October 8 2009 - 25% progression, died in committee
Action: 2009-10-09 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

Summary

Drug Price Competition Act of 2009 - Amends the Federal Food, Drug, and Cosmetic Act to expand the definition of "first applicant" under such Act to allow a generic drug manufacturer that is currently considered an applicant subsequent to a brand-name manufacturer's 180-day exclusivity period to qualify as a first applicant for purposes of filing an abbreviated application for a new drug. Requires such applicant to submit a substantially complete application that contains and lawfully maintains a certification for such drug.

Tracking Information

Register now for our free OneVote public service or GAITS Pro trial account and you can begin tracking this and other legislation, all driven by the real-time data of the LegiScan API. Providing tools allowing you to research pending legislation, stay informed with email alerts, content feeds, and share dynamic reports. Use our new PolitiCorps to join with friends and collegaues to monitor & discuss bills through the process.

Monitor Legislation or view this same bill number from multiple sessions or take advantage of our national legislative search.

Title

Drug Price Competition Act of 2009

Sponsors


History

DateChamberAction
2009-10-09 Referred to the Subcommittee on Health.
2009-10-08 Referred to the House Committee on Energy and Commerce.
2009-10-08 Sponsor introductory remarks on measure. (CR E2487-2488)

Same As/Similar To

SB1315 (Same As) 2009-06-22 - Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Subjects


US Congress State Sources


Bill Comments

feedback